Inclusion Criteria:

- Patients must have histologically confirmed malignancy that is metastatic or
unresectable and for which standard curative or palliative chemotherapy measures do
not exist or are no longer effective

- Patients must not have previously received irinotecan

- Patients must not have received radiation to > 25% of bone marrow

- ECOG performance status =< 2

- Life expectancy of greater than 12 weeks

- Leukocytes >= 3,000/μl

- Absolute neutrophil count >= 1,500/μl

- Platelets >= 100,000/μl

- Total bilirubin within normal institutional limits

- AST(SGOT)/ALT(SGPT) =< 2.5 X institutional upper limit of normal

- Creatinine =< 1.5 mg/dl OR creatinine clearance >= 50 mL/min/1.73 m^2 for patients
with creatinine levels above institutional normal

- Patients must have measurable or evaluable disease

- Patients must have baseline screening for G6PD (glucose-6-phosphate dehydrogenase)
deficiency; G6PD must be no lower than the lower limit of normal prior to starting
study treatment; patients who are above the upper limit of normal may enroll in the
trial

- The effects of Triapine® on the developing human fetus are unknown; for this reason
and because heterocyclic carboxaldehyde thiosemicarbazones as well as other
therapeutic agents used in this trial are known to be teratogenic, women of
child-bearing potential and men must agree to use adequate contraception (hormonal or
barrier method of birth control; abstinence) prior to study entry and for the
duration of study participation; should a woman become pregnant or suspect she is
pregnant while participating in this study, she should inform her treating physician
immediately

- Ability to understand and the willingness to sign a written informed consent document

- Patients must have a baseline screening test for UGT1A1; the UGT1A1 cannot be the 7/7
genotype; patients who have any other combinations (6/6, 6/7, 5/7, etc.) may enroll
in the trial

Exclusion Criteria:

- Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for
nitrosoureas or mitomycin C) prior to entering the study

- Patients who have not recovered from adverse events due to agents administered more
than 4 weeks earlier; patients with grade 1 adverse events from prior therapies are
eligible at the investigator's discretion

- Patients may not be receiving any other investigational agents

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to Triapine® or other agents used in study

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- Pregnant women are excluded from this study because Triapine® is a heterocyclic
carboxaldehyde thiosemicarbazone with the potential for teratogenic or abortifacient
effects; because there is an unknown but potential risk for adverse events in nursing
infants secondary to treatment of the mother with Triapine®, breastfeeding should be
discontinued if the mother is treated with Triapine®; these potential risks may also
apply to other agents used in this study

- Patients with immune deficiency are at increased risk of lethal infections when
treated with marrow-suppressive therapy; therefore, HIV-positive patients receiving
combination anti-retroviral therapy are excluded from the study because of possible
pharmacokinetic interactions with Triapine® or other agents administered during the
study; appropriate studies will be undertaken in patients receiving combination
anti-retroviral therapy when indicated

- Patients with known G6PD deficiency are excluded

- Patients with a history of myocardial infarction or severe pulmonary disease
requiring oxygen are excluded

- Because of the potential for enzyme-inducing anticonvulsant agents (EIACAs) to alter
the metabolism and pharmacokinetics of irinotecan, patients who are taking EIACAs are
excluded

- Metastatic brain or meningeal tumors unless the subject is > 6 months from definitive
therapy, had a negative imaging study within 4 weeks of study entry and is clinically
stable with respect to the tumor at the time of study entry; also the patient must
not be undergoing acute steroid therapy or taper

- Patients with UGT1A1 7/7 genotype are excluded